Lentiviral Hematopoietic Stem Cell Gene Therapy for MLD

NCT07046338 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Metachromatic Leukodystrophy (MLD)

Interventions

GENETIC: Lentiviral TYF-ARSA correction of patient's autologous HSCs

Sponsor

Shenzhen Geno-Immune Medical Institute